Search clinical trials for: Cetuximab (Erbitux)

Total 1034 results

Ruijin Hospital
Xiangya Hospital of Central South University; Chinese PLA General Hospital; West... and other collaborators

Not yet recruiting

Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Colorectal Cancer
National Health Research Institutes, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Unknown

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Colorectal Cancer | Drug Resistance | Mass Spectrometry | RAS-RAF Pathway Deregulation

Taiwan
Eli Lilly and Company

Completed

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Rabin Medical Center
Meir Medical Center; Kaplan Medical Center

Unknown

CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT

Squamous Cell Carcinoma

Israel
HiberCell, Inc.

Completed

Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer

Colorectal Cancer

United States
Sanofi

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Solid Tumor

United States, Israel, Netherlands, Spain
Hadassah Medical Organization
Merck Serono International SA

Terminated

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon

Israel
National University Hospital, Singapore

Unknown

Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)

Nasopharyngeal Cancer | Head and Neck Squamous Cell Carcinoma

Singapore
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Colorectal Neoplasms | Neoplasm | Metastases

United States, Canada
University of Campania "Luigi Vanvitelli"

Recruiting

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Metastatic Colorectal Cancer

Italy
Sichuan Cancer Hospital and Research Institute
Southwest Hospital, China; Affiliated Cancer Hospital & Institute of Guangzhou... and other collaborators

Unknown

Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma

China
The Netherlands Cancer Institute
Merck KGaA, Darmstadt, Germany

Completed

Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

Carcinoma, Squamous Cell of Head and Neck

Netherlands
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Stage III Non-small Cell Lung Cancer

France
Trans Tasman Radiation Oncology Group

Completed

Chemoradiation Treatment for Head and Neck Cancer

Head and Neck Cancer

Australia
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
Nektar Therapeutics

Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Cervical Cancer | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
The Methodist Hospital Research Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (ICE)

Breast Cancer

United States
UNICANCER

Terminated

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

Carcinoma, Squamous Cell of Head and Neck

France
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Merck Sharp & Dohme LLC

Unknown

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle)

Skin Neoplasm

Italy
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb

Terminated

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Lung Cancer

United States
Washington University School of Medicine

Completed

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer (SCCHN)

Carcinoma, Squamous Cell

United States
Boneca Corporation

Terminated

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

Head and Neck Cancer

Finland
Institute of Oncology Ljubljana

Unknown

Treatment Selection According to Skin Reaction to Cetuximab

Head and Neck Cancer

Slovenia
Theagenio Cancer Hospital

Unknown

Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck

Head and Neck Neoplasms | AJCC Stage III/IV

Greece
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
M.D. Anderson Cancer Center

Completed

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Advanced Cancer | Liver Cancer

United States
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, United Kingdom, Canada
Pierre Fabre Medicament
Pfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Completed

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

France, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
NKGen Biotech, Inc.

Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | EGF-R Positive Non-Small... and other conditions
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); National Center for Research... and other collaborators

Completed

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Breast Cancer

United States
Martin Schuler, Prof. Dr. med.

Completed

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (CEBIFOX)

Metastatic Colorectal Cancer

Germany
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Endometrial Cancer

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
Merck KGaA, Darmstadt, Germany
Merck Pte. Ltd., Singapore

Completed

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (APEC)

Metastatic Colorectal Cancer

Singapore
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma

United States
University of Chicago
Verastem, Inc.

Recruiting

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma

United States
Eye & ENT Hospital of Fudan University

Recruiting

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Head and Neck Neoplasms | Metastatic Cancer | Recurrent Disease

China
Fate Therapeutics

Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid Tumor

United States
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Colorectal Cancer | Solid Tumor

United States
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Georgetown University

Withdrawn

Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer (PGx-SELECT)

Head and Neck Cancer
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck | Basaloid Squamous Cell Carcinoma | Undifferentiated Carcinoma | Adenosquamous Cell Carcinoma
Northwell Health

Recruiting

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Glioma | Glioblastoma | Brain Cancer | Brain Tumor | Brain Neoplasm | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Brain Tumor, Recurrent | Brain Neoplasm, Malignant

United States
University of California, San Diego
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Nasopharynx Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer | Cutaneous Squamous Cell Carcinoma | Lip SCC | Sinonasal Carcinoma

United States
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
M.D. Anderson Cancer Center

Not yet recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal Cancer | KRAS G12C Mutations

United States
K-Group, Beta, Inc., a wholly owned subsidiary...
Pfizer

Recruiting

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Australia, United States, Italy, Germany, Poland, Hungary

Search clinical trials for: Cetuximab (Erbitux)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations